Skip to main content
Corterve
10 Studies Recruiting

Clinical Trials Near Seattle, WA

Find research studies actively recruiting participants near Seattle. Studies are run at established research institutions including Fred Hutchinson Cancer Center and UW Medicine.

Top Research Institutions in Seattle

1

Fred Hutchinson Cancer Center

2

UW Medicine

3

Seattle Children's

Recruiting Studies Near Seattle

#1

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

RECRUITINGPHASE3Hoffmann-La Roche

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC).

📍 Goodyear, Arizona📍 Phoenix, Arizona📍 Burbank, California
#2

Autologous Mitochondrial Transplant for Cerebral Ischemia

RECRUITINGNAUniversity of Washington

The investigators propose to infuse healthy autologous mitochondria into cerebral vessels supplying brain tissue experiencing ischemia in patients who undergo standard-of- care endovascular reperfusion therapy.

📍 Seattle, Washington
#3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

RECRUITINGPHASE3Merck Sharp & Dohme LLC

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy

📍 Gilbert, Arizona📍 Phoenix, Arizona📍 Tucson, Arizona
#4

Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others

RECRUITINGNot SpecifiedMichael Shy

This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C). The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window

📍 Los Angeles, California📍 Palo Alto, California📍 Aurora, Colorado
#5

Exploring the Decision to Drink (More) Alcohol Following Manipulations of Stress and Social Context

RECRUITINGNAUniversity of Washington

This preregistration documents an experiment examining the effects of acute stress and social context on alcohol-related decision-making. The study uses a 2x2 factorial design (stress vs. control × social vs. alone) with dyadic recruitment.

📍 Seattle, Washington
#6

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

RECRUITINGPHASE3LeonaBio

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

📍 Scottsdale, Arizona📍 Tucson, Arizona📍 Santa Rosa, California
#7

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

RECRUITINGPHASE3AstraZeneca

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

📍 St Leonards📍 Mississauga, Ontario📍 Stouffville, Ontario
#8

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

RECRUITINGPHASE2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

This is a 2-arm, multi-center, open label study to learn if ATG works the same or better than teplizumab in delaying or preventing Stage 3 Type 1 diabetes. Participants will be administered either 2 infusions of ATG or 14 infusions of teplizumab and will then be followed for at least 12-48 months after administration, depending on timepoint enrolled into the study. If the primary endpoint demonstrates a positive signal and as decided by TrialNet, there is potential for a study extention. This would extend follow-up visits for a possible study duration of about 9 years among the earliest enrollees of the initial study.

📍 Aurora, Colorado📍 New Haven, Connecticut📍 Gainesville, Florida
#9

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

RECRUITINGNot SpecifiedOregon Health and Science University

The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, hemostatic parameter changes, and patient reported quality of life after 6 months of use of either of two commonly used hormonal treatments for menstrual suppression - levonorgestrel intrauterine device (LNG-IUD) and norethindrone acetate (NETA). Under this application the study will compare the two treatments and compare outcomes after LNG-IUD treatment results to a control group without a bleeding disorder, with the goal of determining the benefits and expected outcomes of these treatment options for this population.

📍 Portland, Oregon
#10

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

RECRUITINGNot SpecifiedMilton S. Hershey Medical Center

The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the management AP as well as potentially extending the licensing authorization for CGM to include use in patients with pancreatogenic (Type 3c) DM.

📍 Los Angeles, California📍 Los Angeles, California📍 Stanford, California

Clinical Trials in Seattle: FAQ

How do I find clinical trials near Seattle?

Corterve aggregates all actively recruiting clinical trials near Seattle, WA from the ClinicalTrials.gov database. Simply browse the listings on this page or take our assessment to find trials that may be relevant.

Does it cost anything to take part in a study?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

What research institutions are located in Seattle?

Seattle is home to several leading research institutions, including Fred Hutchinson Cancer Center, UW Medicine, Seattle Children's. These facilities run clinical trials across Oncology, Neurology, Cardiology, and other therapeutic areas.

Ready to see studies near you?

Take our assessment to see research studies recruiting near Seattle that may be relevant. Study teams decide who joins.

See studies near you